吡格列酮
明胶
脂肪性肝炎
脂肪肝
药理学
药物输送
体内
免疫系统
材料科学
化学
生物医学工程
癌症研究
医学
纳米技术
生物
生物化学
免疫学
内科学
糖尿病
2型糖尿病
内分泌学
生物技术
疾病
作者
Wei Xie,Pengpeng Liu,Fei Gao,Yang Gu,Yushao Xiao,Ping Wu,Baiyang Chen,Wei Liu,Quanyan Liu
标识
DOI:10.1016/j.nano.2022.102538
摘要
Non-alcoholic steatohepatitis (NASH) is the major form of chronic liver disease in adults; however, there are no approved drugs for NASH. In this study, we designed the PNM-G-PV method, in which gelatin nanoparticles (G) are loaded with pioglitazone and vitamin E (G-PV) and then encapsulated by the surfaces of platelet–neutrophil hybrid membranes (PNM). Inherited from the natural source cells, the PNM show immune evading ability due to the surface marker comprising a number of “do not eat me” signals and has dual inflammatory enrichment capabilities due to specific surface adhesion molecules. By functionalizing the gelatin nanoparticle biomimetic surfaces, PNM-G can enhance the targeting to inflammatory sites and enrich liver tissue. The high expression of matrix metalloproteinase-9 (MMP-9) at the NASH site enables the gelatin nanoparticles to intelligently respond to degradation and then release vitamin E and pioglitazone for drug treatment. We performed an in vivo analysis of these nanoparticles to monitor changes in triacylglycerol metabolism in liver tissues and assessed the therapeutic efficacy of PNM-G-PV in a NASH rat model. The results showed that PNM-G-PV exhibited better therapeutic efficacy than therapies using G-PV or PV alone. This work explores a new biomedical use of PNM-G-PV and a promising NASH treatment protocol based on a new drug delivery system.
科研通智能强力驱动
Strongly Powered by AbleSci AI